Pharmacyclics News

This is a continuation of my previous article on biotechnology stocks to watch ahead of ASCO 2012.

Let's take a look at how it got there and whether clear skies are still in the forecast.

There are two companies making headlines these days on their trials and drugs targeting and related to Leukemia patients.

SUNNYVALE, Calif., May 22, 2012 /PRNewswire/ -- Pharmacyclics, Inc. today announced that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib have been selected for oral presentations at the 17th Congress of the European Hematology Association , June 14-17, 2012 in Amsterdam, The Netherlands.

PCYC ) went up today, reaching and then surpassing its previous 52-week high of $31. The stock was trading on above-average volume.

So much has been written about the significant levels of insider selling taking place at the moment.

The firm currently has a "buy" rating on the stock. PCYC has been the subject of a number of other recent research reports.

Pharmacyclics : Rodman & Renshaw reiterated its rating of Mkt Outperform for this company and changed its price target from $22 to $40. Nu Skin : Stifel Nicolaus reiterated its rating of Buy for this company and changed its price target from $60 to $51. Informatica : Mizuho reiterated its rating of Neutral for this company and changed its price ... (more)

The firm currently has an "outperform" rating on the stock. Shares of Pharmacyclics opened at 29.31 on Thursday.

Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib at the 2012 Annual Meeting of the American Society of Clinical Oncology SUNNYVALE, Calif., May 17, 2012 /PRNewswire/ -- Pharmacyclics, Inc.

All of the trading has occurred at the January 2013 18 strike, with the majority of the puts crossing at the bid price, suggesting they were sold.

CAMBRIDGE, Mass. -- -- Epizyme, Inc. , a company leading the discovery and development of personalized therapeutics for patients with genetically-defined cancers, based on breakthroughs in the field of epigenetics, today announced that Dr.

Pharmacyclics, Inc. today reported financial results and recent developments for its fiscal third quarter ended March 31, 2012.

Gilead is garnering a huge amount of attention from investors owing to the hepatitis C virus pipeline it got from the Pharmasset acquisition.